Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02654132 · ClinicalTrials.gov registry record · Phase 2
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT02654132 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 117 participants.
The verdict
NCT02654132, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Elotuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-03-18 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02654132
The ClinicalTrials.gov registry entry for NCT02654132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02654132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02654132 about?
NCT02654132 is a clinical study titled "An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)". The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.
What is the current status of trial NCT02654132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2016-03-18. Estimated completion is 2021-10-21.
What interventions are being tested in trial NCT02654132?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT02654132?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.